β-受体阻滞剂在心力衰竭治疗中的应用  

Application of beta blockers in the treatment of patients with heart failure

作　　者：华琦[1] 李静[1] 

机构地区：[1]首都医科大学宣武医院心脏中心,北京100053

出　　处：《中国实用内科杂志》2010年第3期204-206,共3页Chinese Journal of Practical Internal Medicine

摘　　要：β-受体阻滞剂可以分为非选择性、选择性和具有血管扩张作用的β-受体阻滞剂3类。这类药物可以通过β信号系统上调、逆转重构、改善收缩和舒张功能、抗心律失常以及抗缺血等作用改善心力衰竭患者预后。随机对照临床研究已经证实其可以降低心力衰竭患者病死率、提高生存质量。各种指南也推荐其应用于心力衰竭的治疗。应用该类药物应该注意用药的时机、剂量、时程和禁忌证。Beta blocker can be categorized by non-selective agents, selective agents and agents with vasodilatory effect. Beta blocker therapy represents a major advance in the treat- ment of heart failure patients. The mechanisms include up-regulation of beta receptor, reversing remodeling, improving contractile and diastolic function, antiarrhythmia and anti-ischemia. Evidences from randomized controlled clinical trials have supported its use in the treatment of patients with heart failure to decrease mortality and improve life quality. Guidelines with various versions recommend that β-blockers are indicated for patients with symptomatic or asymptomatic heart failure and a depressed ejection fraction of lower than 40%. There is something to be noticed for rational use of β-blockers such as timing, dosage, duration and contraindications.

关 键 词：Β-受体阻滞剂 心力衰竭 

分 类 号：R5[医药卫生—内科学]